India, July 26 -- AstraZeneca PLC (AZN) is scheduled to report the second-quarter results on July 27, 2026.
AstraZeneca, as a biopharmaceutical company, offers multiple products for oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune therapies, and therapies for rare diseases. AstraZeneca's blockbuster drugs include Farxiga, Tagrisso, Imfinzi, Ultomiris, and emerging blockbusters include Calquence, Lynparza, Symbicort, Fasenra, and Soliris.
First Quarter Of 2026
For the first quarter of 2026, the company's profit attributable to owners of the parent increased to $3.08 billion, or $1.99 per share, from $2.92 billion, or $1.88 per share, in the prior year.
Total revenue jumped to $15.29 billion fr...